CASP2 and hematopoietic and lymphoid system neoplasm: Reduced expression of Casp2 was reported in blood cancer and several solid tumors.39, 40, 41 High Casp2 level is associated with poor survival in human neuroblastoma patients.42 Even so, mutations of CASP2 are rare in various human cancers.43, 44 Therefore, direct mutational inactivation of CASP2 might not fully explain its decline or loss-of-function in human tumors.